摘要
Lung cancer is one of the malignant tumors with the fastest increasing morbidity and mortality in the world.Although surgical techniques have been improved and new chemotherapy drugs and local treatment methods keep emerging in recent years,the overall therapeutic effect on lung cancer is unsatisfactory.The advent of immunotherapy has brought about a major revolution in treating lung cancer,especially for non-small cell lung cancer(NSCLC).However,based on the heterogeneity of cancer types,not all patients with NSCLC can benefit from immunotherapy.It is essential to find reliable biomarkers to guide clinical immunotherapy.Compared with histological biopsy,biomarker-based detection not only has the advantages of early and non-invasive detection,but also can reflect the tumor’s biological characteristics and the body’s immune status.This article reviews the research progression on immunotherapy biomarkers of peripheral blood in NSCLC,with the aim of providing references for the evaluation of immunotherapy efficacy and prognosis of patients with NSCLC.
